2025-12-03 - Analysis Report
Okay, here's a comprehensive report on Eli Lilly (LLY) based on the provided data:

**1. Return Rate Comparison**

*   **Company Overview:** Eli Lilly and Co is a global pharmaceutical company that develops and markets a wide range of medicines.
*   **LLY Cumulative Return:** 297.05%
*   **VOO (S&P 500) Cumulative Return:** 100.36%
*   **Divergence:**
    *   Current: 207.5
    *   Relative Divergence: 85.5

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) by a wide margin. The current divergence is high, placing it in the top quartile of its historical divergence range. This suggests strong relative performance. The relative divergence of 85.5 indicates that the current divergence is high compared to the past fluctuation range.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B)  |
|------------|---------|-------|---------|-------|---------|
| 2015-2017  | 11.0%   | 76.1% | -17.0%  | -0.0  | 75.7    |
| 2016-2018  | 39.0%   | 68.9% | 24.0%   | -0.0  | 103.7   |
| 2017-2019  | 41.0%   | 68.9% | 19.0%   | 0.4   | 117.8   |
| 2018-2020  | 34.0%   | 79.8% | 10.0%   | 0.4   | 151.3   |
| 2019-2021  | 53.0%   | 79.8% | 7.0%    | 0.5   | 247.5   |
| 2020-2022  | 64.0%   | 79.8% | 65.0%   | 0.4   | 327.9   |
| 2021-2023  | 125.0%  | 78.9% | 124.0%  | 0.2   | 522.4   |
| 2022-2024  | 134.0%  | 81.2% | 113.0%  | 0.2   | 691.8   |
| 2023-2025  | 188.0%  | 83.5% | 124.0%  | 0.2   | 939.9   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate has steadily increased over the analyzed periods, reflecting strong growth. The most recent period (2023-2025) shows exceptional growth.
*   **MDD:** Maximum Drawdown (MDD) remains high, indicating significant volatility and potential for losses during downturns.
*   **Alpha:** Alpha is generally positive and very high in recent periods, indicating that LLY is generating returns above what would be expected based on market movements alone.
*   **Beta:** Beta is relatively low, suggesting LLY is less sensitive to market fluctuations than the S&P 500. The Beta decreased in recent periods, and the Beta is at very low level.
*   **Cap(B):** The Market Capitalization has increased dramatically, reflecting investor confidence and company growth.

**2. Recent Stock Price Fluctuations**

*   **Current Price:** 1048.775
*   **Last Market Data:** {'price': 1048.8269, 'previousClose': 1057.89, 'change': -0.86}
*   **5-day SMA:** 1081.737
*   **20-day SMA:** 1013.3583
*   **60-day SMA:** 866.4326

**Analysis:** The current price is below the 5-day SMA but above the 20-day and 60-day SMAs. This suggests a possible short-term pullback but an overall upward trend remains strong.  The price decline from the previous close (change of -0.86) needs monitoring.

**3. RSI, PPO and Market Risk Indicator**

*   **Market Risk Indicator (MRI):** 0.9 (Medium Investment Recommended)
*   **RSI:** 68.31
*   **PPO:** -0.2588
*   **Hybrid Signal:** cash_0%_Buy 100% of cash
*   **Recent (20 days) relative divergence change:** 1.1 (+): 단기상승 (Short-term rise)
*   **Expected Return (%):** 47.1

**Analysis:**

*   The MRI of 0.9 suggests the market conditions are still favorable for investment.
*   The RSI is approaching overbought territory (above 70), which could indicate a potential pullback.
*   The PPO being slightly negative suggests that the short-term momentum is slightly weaker than the long-term trend.
*   The hybrid signal recommends buying.
*   The increase in recent relative divergence confirms a short-term upward trend.
*   The expected return of 47.1% is extremely high and suggests continued strong performance is anticipated.

**4. Recent News & Significant Events**

*   **Price Cuts:** LLY is lowering prices on Zepbound vials for cash buyers. This could impact revenue, but also increase market share.
*   **Analyst Upgrades:** BMO Capital reiterated an Outperform rating. Other reports highlight positive technicals and reasons to buy the stock.
*   **GLP-1 Boom:** Coverage highlights the potential impact of GLP-1 drugs on the company.
*   **Stock Slides:** One report mentions a slide in LLY stock amid other market news, possibly related to profit-taking.

**Analysis:** Recent news is mixed. The lowering of prices could be a concern for profitability, but the analyst ratings and GLP-1 drug boom coverage are positive signals. The stock slide should be monitored but may be a temporary correction.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.77)
*   **Target Price:** Average $1040.89 (High: $1500.00, Low: $770.00)

**Analysis:** Analyst consensus is strongly bullish on LLY. The average target price is slightly below the current price, implying limited near-term upside according to the average analyst, but some analysts have much higher targets. There are no recent rating changes listed.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-10-30 | 6.22 | 17.60 B$   |
| 2025-08-07 | 6.3  | 15.56 B$   |
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2025-10-30 | 1.08 | 11.44 B$   |

**Analysis:** Earnings per share (EPS) and revenue have shown significant growth over the past year. The EPS growth from 2024-10-30 to 2025-10-30 is significant. The data entry on 2025-10-30 seems to be duplicated, it should be corrected.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.60B    | 82.91%        |
| 2025-06-30   | $15.56B    | 84.27%        |
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-09-30   | $23.79B    | 23.46%    |
| 2025-06-30   | $18.27B    | 30.98%    |
| 2025-03-31   | $15.76B    | 17.50%    |
| 2024-12-31   | $14.19B    | 31.07%    |
| 2024-09-30   | $14.24B    | 6.81%     |

**Analysis:**

*   Revenue has been increasing steadily over the last year, indicating strong sales growth.
*   Profit margins are exceptionally high, indicating strong efficiency and pricing power.
*   Equity has increased significantly, suggesting retained earnings and potentially successful capital raising.
*   Return on Equity (ROE) is volatile but generally high, indicating efficient use of shareholder equity to generate profits.

**7. Comprehensive Analysis (Summary)**

Eli Lilly (LLY) demonstrates strong financial performance and growth potential.

*   **Strengths:**
    *   Significant outperformance of the S&P 500.
    *   High and growing revenue and earnings.
    *   Excellent profit margins and ROE.
    *   Strong analyst consensus and bullish sentiment.
    *   Positive news surrounding GLP-1 drugs and analyst upgrades.
    *   High expected return.
*   **Weaknesses/Risks:**
    *   High maximum drawdown indicates volatility.
    *   Potential pullback indicated by RSI nearing overbought territory.
    *   Recent price declines and price cuts (Zepbound) need monitoring.
    *   Average analyst target price slightly below current price.

**Overall Recommendation:** Based on the provided data, Eli Lilly appears to be a strong investment. However, investors should be aware of the stock's volatility and monitor the potential impact of price cuts and any future price declines. Considering the high RSI, it might be prudent to wait for a potential pullback before initiating or adding to a position.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.